

DAFTAR PUSTAKA

- Abe, O., Abe, R., & Enomoto, K. (2005). Early breast cancer trialists' collaborative g: effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet*, 365, 1687-1717.
- Acs, B., Fredriksson, I., Rönnlund, C., Hagerling, C., Ehinger, A., Kovács, A., Røge, R., Bergh, J., & Hartman, J. (2021). Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study. *Cancers*, 13(5), 1166. <https://doi.org/10.3390/cancers13051166>
- Agustina, R. (2015). Peran derajat differensiasi histopatologik dan stadium klinis pada rekurensi kanker payudara. *Jurnal Majority*, 4(7), 129-134.
- Akram, M., Iqbal, M., Daniyal, M., & Khan, A. U. (2017). Awareness and current knowledge of breast cancer. *Biological research*, 50, 1-23. <https://doi.org/10.1186/s40659-017-0140-9>.
- Abukhdeir, A. M., & Park, B. H. (2008). P21 and p27: roles in carcinogenesis and drug resistance. *Expert reviews in molecular medicine*, 10, e19. <https://doi.org/10.1017/S1462399408000744>.
- Ali, R. M. M., McIntosh, S. A., & Savage, K. I. (2021). Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy. *Genes, chromosomes & cancer*, 60(5), 358–372. <https://doi.org/10.1002/gcc.22921>.

Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., ... & Wolff, A. C. (2020). Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. <https://doi.org/10.1200/jco.19.02309>.

Amer, A., Nagah, A., Tian, T., and Zhang, X. (2020). Mutation Mechanisms of Breast Cancer Among the Female Population in China. *Curr. Bioinformatics* 15 (3), 253–259. doi:10.2174/1574893615666191220141548.

André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., ... & Juric, D. (2019). Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. *New England Journal of Medicine*, 380(20), 1929-1940. DOI: 10.1056/NEJMoa1813904.

Anwar, S. L., Avanti, W. S., Nugroho, A. C., Choridah, L., Dwianingsih, E. K., Harahap, W. A., ... & Wulaningsih, W. (2020). Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia. *World Journal of Surgical Oncology*, 18, 1-16. <https://doi.org/10.1186/s12957-020-01893-w>.

Ashworth, A. (2008). A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. *Journal of Clinical Oncology*, 26(22), 3785-3790.

Aucamp, J., Bronkhorst, A. J., Badenhorst, C. P., & Pretorius, P. J. (2018). The diverse origins of circulating cell-free DNA in the human body: a critical re-

evaluation of the literature. *Biological Reviews*, 93(3), 1649-1683.
<https://doi.org/10.1111/brv.12413>.

Aznab, M., Shojae, S., Sorkheh, A. G., & Rezaei, M. (2023). The Survival of Patients with Triple Negative Breast Cancer Undergoing Chemotherapy Along with Lifestyle Change Interventions: Survival of TNBC patients. *Archives of Breast Cancer*, 10(1), 66-73. <https://doi.org/10.32768/abc.202310166-73>.

Badve, S. S., Penault-Llorca, F., Reis-Filho, J. S., Deurloo, R., Siziopikou, K. P., D'Arrigo, C., & Viale, G. (2022). Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. *Journal of the National Cancer Institute*, 114(5), 664–675.
<https://doi.org/10.1093/jnci/djab121>

Baselga, J., Dent, S. F., Cortés, J., Im, Y. H., Diéras, V., Harbeck, N., ... & Jacot, W. (2018). Phase III study of taselisib (GDC-0032)+ fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from sandpiper. DOI: 10.1200/JCO.2018.36.18_suppl.LBA1006.

Bite, S. (2004). Lifetime Probability among Females of Dying of Cancer. *JNCI J. Natl. Cancer Inst*, 96, 1311-1321.

Brewer, H. R., Jones, M. E., Schoemaker, M. J., Ashworth, A., & Swerdlow, A. J. (2017). Family history and risk of breast cancer: an analysis accounting for family structure. *Breast cancer research and treatment*, 165, 193-200.
<https://doi.org/10.1007/s10549-017-4325-2>.

Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., ... & Hortobagyi, G. N. (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2–positive operable breast cancer. *Journal of clinical oncology*, 23(16), 3676-3685. DOI: 10.1200/JCO.2005.07.032.

Cardoso, F, S. Kyriakides, S. Ohno, et. al, on behalf of the cx Guidelines Committee. (2019). Early Breast Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 30(8), 1194-1220. doi:10.1093/annonc/mdz173.

Casadei, S., Norquist, B. M., Walsh, T., Stray, S., Mandell, J. B., Lee, M. K., ... & King, M. C. (2011). Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. *Cancer research*, 71(6), 2222-2229. <https://doi.org/10.1158/0008-5472.CAN-10-3958>.

Colleoni, M., Sun, Z., Price, K. N., Karlsson, P., Forbes, J. F., Thürlimann, B., ... & Goldhirsch, A. (2016). Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. *Journal of clinical oncology*, 34(9), 927. doi: 10.1200/JCO.2015.62.3504.

Cong, Y., Qiao, G., Zou, H., Lin, J., Wang, X., Li, X., ... & Zhu, S. (2015). Invasive cribriform carcinoma of the breast: a report of nine cases and a review of the

literature. *Oncology Letters*, 9(4), 1753-1758.
<https://doi.org/10.3892/ol.2015.2972>.

Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., ... & Loibl, S. (2018). Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *The lancet oncology*, 19(1), 40-50.
[https://doi.org/10.1016/S1470-2045\(17\)30904-X](https://doi.org/10.1016/S1470-2045(17)30904-X).

Ding, Y., Ding, K., Qian, H., Yu, X., Zou, D., Yang, H., ... & Ding, X. (2020). Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre-and post-neoadjuvant chemotherapy in breast cancer. *PLoS One*, 15(4), e0231895.
<https://doi.org/10.1371/journal.pone.0231895>.

Dowsett, M., & Dunbier, A. K. (2008). Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. *Clinical Cancer Research*, 14(24), 8019-8026. <https://doi.org/10.1158/1078-0432.CCR-08-0974>.

Duffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017). Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). *European journal of cancer*, 75, 284-298. <https://doi.org/10.1016/j.ejca.2017.01.017>.

Dumitru, A., Procop, A., Iliesiu, A., Tampa, M., Mitache, L., Costache, M., Sajin, M., Lazaroiu, A., & Cirstoiu, M. (2015). Mucinous Breast Cancer: a Review

Study of 5 Year Experience from a Hospital-Based Series of Cases. *Maedica*, 10(1), 14–18.

Dunnwald, L. K., Rossing, M. A., & Li, C. I. (2007). Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. *Breast cancer research*, 9, 1-10. <https://doi.org/10.1186/bcr1639>.

Erkko, H., Dowty, J. G., Nikkilä, J., Syrjäkoski, K., Mannermaa, A., Pylkäs, K., ... & Hopper, J. L. (2008). Penetrance analysis of the PALB2 c. 1592delT founder mutation. *Clinical Cancer Research*, 14(14), 4667-4671. <https://doi.org/10.1158/1078-0432.CCR-08-0210>.

Erol, A., Ho, A. M. C., Winham, S. J., & Karpayak, V. M. (2019). Sex hormones in alcohol consumption: a systematic review of evidence. *Addiction biology*, 24(2), 157-169. <https://doi.org/10.1111/adb.12589>.

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., ... & Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International journal of cancer*, 136(5), E359-E386. <https://doi.org/10.1002/ijc.292>.

Frelander, A., Brown, L. J., Parker, A., Segara, D., Portman, N., Lau, B., & Lim, E. (2021). Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. *Genes*, 12(2), 285. <https://doi.org/10.3390/genes12020285>.

Fritz, P., Bendrat, K., Sonnenberg, M., Trautmann, C., Ott, G., Heidemann, E., ... & Niendorf, A. (2014). Tubular breast cancer. A retrospective study. *Anticancer Research*, 34(7), 3647-3656.

Gamble, P., Jaroensri, R., Wang, H., Tan, F., Moran, M., Brown, T., ... & Chen, P. H. C. (2021). Determining breast cancer biomarker status and associated morphological features using deep learning. *Communications medicine*, 1(1), 14. <https://doi.org/10.1038/s43856-021-00013-3>.

Gennari, A., André, F., Barrios, C. H., Cortes, J., De Azambuja, E., DeMichele, A., ... & Harbeck, N. (2021). ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆. *Annals of oncology*, 32(12), 1475-1495. <https://doi.org/10.1016/j.annonc.2021.09.019>.

Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., ... & Wood, W. C. (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Annals of oncology*, 24(9), 2206-2223. <https://doi.org/10.1093/annonc/mdt303>.

Hammerl, D., Smid, M., Timmermans, A. M., Sleijfer, S., Martens, J. W. M., & Debets, R. (2018). Breast cancer genomics and immuno-oncological markers to guide immune therapies. In *Seminars in cancer biology* (Vol. 52, pp. 178-188). Academic Press. <https://doi.org/10.1016/j.semcancer.2017.11.003>.

Hammond, M. E., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., ... & Wolff, A. (2010). College of American Pathologists guideline

- recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol*, 28(16), 2784-2795.
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. *cell*, 144(5), 646-674. <https://doi.org/10.1016/j.cell.2011.02.013>.
- Harbeck N. (2022). Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. *Breast (Edinburgh, Scotland)*, 62 Suppl 1(Suppl 1), S12–S16. <https://doi.org/10.1016/j.breast.2022.01.006>
- Helmi, A. F., Khambri, D., & Rustam, R. (2021). The Relationship of Breast Cancer Subtypes with the Event of Metastasis in Dr. M. Djamil Hospital Padang. *Bioscientia Medicina: Journal of Biomedicine and Translational Research*, 5(4), 399-405. <https://doi.org/10.32539/bsm.v5i4.410>.
- Henry, N. L., & Cannon-Albright, L. A. (2019). Breast cancer histologic subtypes show excess familial clustering. *Cancer*, 125(18), 3131-3138. <https://doi.org/10.1002/cncr.32198>.
- Holler, A., Nguyen-Strauli, B. D., Frauchiger-Heuer, H., & Ring, A. (2023). Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?. *Breast cancer (Dove Medical Press)*, 15, 525–540. <https://doi.org/10.2147/BCTT.S340741>.
- Horn, J., & Vatten, L. J. (2017). Reproductive and hormonal risk factors of breast cancer: a historical perspective. *International journal of women's health*, 265-272. <https://doi.org/10.2147/IJWH.S129017>.

- Hurvitz, S. A., Martin, M., Press, M. F., Chan, D., Fernandez-Abad, M., Petru, E., ... & Slamon, D. J. (2020). Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+/HER2- breast cancer. *Clinical Cancer Research*, 26(3), 566-580. <https://doi.org/10.1158/1078-0432.CCR-19-1425>.
- Inic, Z., Zegarac, M., Inic, M., Markovic, I., Kozomara, Z., Djuriscic, I., ... & Jancic, S. (2014). Difference between luminal A and luminal B subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information. *Clinical Medicine Insights: Oncology*, 8, CMO-S18006. <https://doi.org/10.4137/CMO.S18006>.
- Ishii, K., Morii, N., & Yamashiro, H. (2019). Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. *Core evidence*, 51-70. <https://doi.org/10.2147/CE.S217848>.
- Jacobs, A. T., Castaneda-Cruz, D. M., Rose, M. M., & Connelly, L. (2022). Targeted therapy for breast cancer: An overview of drug classes and outcomes. *Biochemical Pharmacology*, 204, 115209. <https://doi.org/10.1016/j.bcp.2022.115209>
- James, F. R., Wootton, S., Jackson, A., Wiseman, M., Copson, E. R., & Cutress, R. I. (2015). Obesity in breast cancer—what is the risk factor?. *European journal of cancer*, 51(6), 705-720. <https://doi.org/10.1016/j.ejca.2015.01.057>.

- Javaeed, A. (2018). Breast cancer screening and diagnosis: a glance back and a look forward. *Int. J. Community Med. Public Health*, 5, 4997-5002. <https://doi.org/10.18203/2394-6040.ijcmph20184605>.
- Joshi, S. C., Khan, F. A., Pant, I., & Shukla, A. N. (2007). Role of radiotherapy in early breast cancer: an overview. *International journal of health sciences*, 1(2), 259-264.
- Jung, S., Wang, M., Anderson, K., Baglietto, L., Bergkvist, L., Bernstein, L., ... & Smith-Warner, S. A. (2016). Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies. *International journal of epidemiology*, 45(3), 916-928. <https://doi.org/10.1093/ije/dyv156>.
- Jurčić, P., Krušlin, B., Gatalica, Z., Sanati, S., & Vranić, S. (2016). Breast carcinoma with neuroendocrine features: a brief review. *Endo Oncology and Metab*, 2, 138-45. DOI: 10.21040/eom/2016.2.2.6.
- Kalli, S., Semine, A., Cohen, S., Naber, S. P., Makim, S. S., & Bahl, M. (2018). American joint committee on cancer's staging system for breast cancer: what the radiologist needs to know. *Radiographics*, 38(7), 1921-1933. <https://doi.org/10.1148/rg.2018180056>.
- Kemenkes RI. (2023). Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/2197/2023 Tentang Formularium Nasional. Jakarta: Departemen Kesehatan Republik Indonesia.
- Key, T. J., Appleby, P. N., Reeves, G. K., Travis, R. C., Alberg, A. J., Barricarte, A., ... & Vineis, P. (2013). Sex hormones and risk of breast cancer in

premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. *Lancet Oncol*, 14(10), 1009-1019. doi: 10.1016/s1470-2045(13)70301-2.

Krishnamurti, U., & Silverman, J. F. (2014). HER2 in breast cancer: a review and update. *Advances in anatomic pathology*, 21(2), 100-107. doi: 10.1097/PAP.0000000000000015.

Kumar, P., & Aggarwal, R. (2016). An overview of triple-negative breast cancer. *Archives of gynecology and obstetrics*, 293, 247-269. <https://doi.org/10.1007/s00404-015-3859-y>.

Kwapisz, D. (2017). Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. *Breast cancer research and treatment*, 166, 41-54. <https://doi.org/10.1007/s10549-017-4385-3>.

Li, Y., Du, F., Zhu, W., & Xu, B. (2017). Neuroendocrine carcinoma of the breast: a review of 126 cases in China. *Chinese Journal of Cancer*, 36(1), 1-4. <https://doi.org/10.1186/s40880-017-0211-x>.

Loibl, S., & Gianni, L. (2017). HER2-positive breast cancer. *The Lancet*, 389(10087), 2415-2429. [https://doi.org/10.1016/S0140-6736\(16\)32417-5](https://doi.org/10.1016/S0140-6736(16)32417-5).

Luchini, C., Bibeau, F., Ligtenberg, M. J. L., Singh, N., Nottegar, A., Bosse, T., ... & Scarpa, A. (2019). ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based

approach. *Annals of Oncology*, 30(8), 1232-1243.
<https://doi.org/10.1093/annonc/mdz116>.

Luporsi, E., Andre, F., Spyrtos, F., Martin, P. M., Jacquemier, J., Penault-Llorca, F., ... & Bellocq, J. P. (2012). Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. *Breast cancer research and treatment*, 132, 895-915. <https://doi.org/10.1007/s10549-011-1837-z>.

Ma, X., Zhang, Y., Wang, S., Wei, H., & Yu, J. (2021). Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review. *Journal of Cancer*, 12(5), 1318–1333. <https://doi.org/10.7150/jca.49174>.

Makki, J. (2015). Diversity of breast carcinoma: histological subtypes and clinical relevance. *Clinical medicine insights: Pathology*, 8, CPath-S31563. <https://doi.org/10.4137/CPath.S31563>.

Matro, J. M., Li, T., Cristofanilli, M., Hughes, M. E., Ottesen, R. A., Weeks, J. C., & Wong, Y. N. (2015). Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome. *Clinical breast cancer*, 15(1), 1-7. <https://doi.org/10.1016/j.clbc.2014.05.005>.

Marino, F., Buono, S., Montella, M., Giannatiempo, R., Messina, F., Casaretta, G., Arpino, G., Vita, G., Fiorentino, F., Insabato, L., Sgambato, A., Orditura, M., Franco, R., & Accardo, M. (2023). NTRK gene aberrations in triple-negative breast cancer: detection challenges using IHC, FISH, RT-PCR, and NGS. *The*

journal of pathology. *Clinical research*, 9(5), 367–377.
<https://doi.org/10.1002/cjp2.324>.

Marrazzo, E., Frusone, F., Milana, F., Sagona, A., Gatzemeier, W., Barbieri, E., ... & Tinterri, C. (2020). Mucinous breast cancer: a narrative review of the literature and a retrospective tertiary single-centre analysis. *The Breast*, 49, 87-92. <https://doi.org/10.1016/j.breast.2019.11.002>.

Masood, S. (2016). Breast cancer subtypes: morphologic and biologic characterization. *Women's Health*, 12(1), 103-119.
<https://doi.org/10.2217/whe.15.99>.

Mavaddat, N., Barrowdale, D., Andrulis, I. L., Domchek, S. M., Eccles, D., Nevanlinna, H., ... & Antoniou, A. C. (2012). Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology, Biomarkers & Prevention*, 21(1), 134-147.
<https://doi.org/10.1158/1055-9965.EPI-11-0775>.

McGuire, A., Brown, J. A., Malone, C., McLaughlin, R., & Kerin, M. J. (2015). Effects of age on the detection and management of breast cancer. *Cancers*, 7(2), 908-929. <https://doi.org/10.3390/cancers7020815>.

Melchor, L., & Benítez, J. (2008). An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. *Carcinogenesis*, 29(8), 1475-1482. DOI:10.1093/carcin/bgn157.

Mohammed, H., Russell, I. A., Stark, R., Rueda, O. M., Hickey, T. E., Tarulli, G. A., ... & Carroll, J. S. (2015). Progesterone receptor modulates ER α action in breast cancer. *Nature*, 523(7560), 313-317. <https://doi.org/10.1038/nature14583>.

Mollon, L., Aguilar, A., Anderson, E., Dean, J., Davis, L., Warholak, T., ... & Tang, D. (2018). A systematic literature review of the prevalence of PIK3CA mutations and mutation hotspots in HR+/HER2-metastatic breast cancer. *Cancer Research*, 78(13_Supplement), 1207-1207. <https://doi.org/10.1158/1538-7445.AM2018-1207>.

Nascimento, R. G., & Otoni, K. M. (2020). Histological and molecular classification of breast cancer: what do we know?. *Mastology*, 30, 1-8. DOI: 10.29289/25945394202020200024.

Najjar, S., & Allison, K. H. (2022). Updates on breast biomarkers. *Virchows Archiv*, 480(1), 163-176. doi: 10.1007/s00428-022-03267-x.

National Cancer Institute: PDQ® Breast Cancer Screening. Bethesda, MD: National Cancer Institute. Date last modified <04/13/2015>. Available at: <http://www.cancer.gov/types/breast/patient/breast-screening-pdq>. Accessed <10/02/2023>.

Neves Rebello Alves, L., Dummer Meira, D., Poppe Merigueti, L., Correia Casotti, M., do Prado Ventorim, D., Ferreira Figueiredo Almeida, J., Pereira de Sousa, V., Cindra Sant'Ana, M., Gonçalves Coutinho da Cruz, R., Santos Louro, L., Mendonça Santana, G., Erik Santos Louro, T., Evangelista Salazar, R., Ribeiro

- Campos da Silva, D., Stefani Siqueira Zetum, A., Silva Dos Reis Trabach, R., Imbroisi Valle Errera, F., de Paula, F., de Vargas Wolfgramm Dos Santos, E., Fagundes de Carvalho, E., ... Drumond Louro, I. (2023). Biomarkers in Breast Cancer: An Old Story with a New End. *Genes*, 14(7), 1364. <https://doi.org/10.3390/genes14071364>
- Ng, J., & Shuryak, I. (2014). Minimizing second cancer risk following radiotherapy: current perspectives. *Cancer management and research*, 1-11. <https://doi.org/10.2147/CMAR.S47220>.
- Nguyen, X., Hooper, M., Borlagdan, J. P., & Palumbo, A. (2021). A review of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer. *Annals of Pharmacotherapy*, 55(11), 1410-1418. <https://doi.org/10.1177/1060028021998320>.
- O'Meara, T. A., & Tolaney, S. M. (2021). Tumor mutational burden as a predictor of immunotherapy response in breast cancer. *Oncotarget*, 12(5), 394–400. <https://doi.org/10.18632/oncotarget.27877>.
- Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H. J., Morse, M. A., ... & André, T. (2017). Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *The lancet oncology*, 18(9), 1182-1191. [https://doi.org/10.1016/S1470-2045\(17\)30422-9](https://doi.org/10.1016/S1470-2045(17)30422-9).
- Pandit, P., Patil, R., Palwe, V., Gandhe, S., Patil, R., & Nagarkar, R. (2019). Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional

- Experience of 2062 Patients. *European journal of breast health*, 16(1), 39–43.
<https://doi.org/10.5152/ejbh.2019.4997>.
- Pascual, J., Attard, G., Bidard, F. C., Curigliano, G., de Mattos-Arruda, L., Diehn, M., ... & Turner, N. C. (2022). ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group. *Annals of Oncology*, 33(8), 750-768. <https://doi.org/10.1016/j.annonc.2022.05.520>.
- Patani, N., Martin, L. A., & Dowsett, M. (2013). Biomarkers for the clinical management of breast cancer: international perspective. *International journal of cancer*, 133(1), 1-13. <https://doi.org/10.1002/ijc.27997>.
- Pathmanathan, N., Balleine, R. L., Jayasinghe, U. W., Bilinski, K. L., Provan, P. J., Byth, K., ... & Boyages, J. (2014). The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. *Journal of clinical pathology*, 67(3), 222-228. <http://dx.doi.org/10.1136/jclinpath-2013-201793>.
- Paluch-Shimon, S., Cherny, N. I., de Vries, E. G., Dafni, U., Piccart, M. J., Latino, N. J., & Cardoso, F. (2020). Application of the ESMO-Magnitude of Clinical Benefit Scale (V. 1.1) to the field of early breast cancer therapies. *ESMO open*, 5(5), e000743. <https://doi.org/10.1136/esmoopen-2020-000743>.
- Polley, M. Y. C., Leung, S. C., McShane, L. M., Gao, D., Hugh, J. C., Mastropasqua, M. G., ... & Nielsen, T. O. (2013). An international Ki67 reproducibility study. *Journal of the National Cancer Institute*, 105(24), 1897-1906. <https://doi.org/10.1093/jnci/djt306>.

- Prasad, V., Kaestner, V., & Mailankody, S. (2018). Cancer drugs approved based on biomarkers and not tumor type—FDA approval of pembrolizumab for mismatch repair-deficient solid cancers. *JAMA oncology*, 4(2), 157-158. doi:10.1001/jamaoncol.2017.4182.
- Provenzano, E., Ulaner, G. A., & Chin, S. F. (2018). Molecular classification of breast cancer. *PET clinics*, 13(3), 325-338. <https://doi.org/10.1016/j.cpet.2018.02.004>.
- Puspitawati, D. A. (2018). Sistem pakar diagnosis penyakit kanker payudara dan cara penanganannya. *Jurnal Techno Nusa Mandiri*, 15(2), 129-136. <https://doi.org/10.33480/techno.v15i2.22>.
- Qi, Y., Zhang, L., Wang, Z., Kong, X., Zhai, J., Fang, Y., & Wang, J. (2021). Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence. *Frontiers in pharmacology*, 12, 653521. <https://doi.org/10.3389/fphar.2021.653521>
- Rahman, G. A. (2011). Breast conserving therapy: a surgical technique where little can mean more. *Journal of surgical technique and case report*, 3(1). DOI: 10.4103/2006-8808.78459.
- Rehan Haider. (2023). Anatomy of the Breast. *International Journal of Scientific Multidisciplinary Research*, 1(5), 401-422. <https://doi.org/10.55927/ijsmr.v1i5.4394>.
- Riccardi, F., Colantuoni, G., Diana, A., Mocerino, C., Cartenì, G., Lauria, R., ... & Orditura, M. (2018). Exemestane and Everolimus combination treatment of

hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety. *Molecular and clinical oncology*, 9(3), 255-263. <https://doi.org/10.3892/mco.2018.1672>.

Ritte, R., Lukanova, A., Berrino, F., Dossus, L., Tjønneland, A., Olsen, A., ... & Kaaks, R. (2012). Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. *Breast cancer research*, 14, 1-14. <https://doi.org/10.1186/bcr3186>.

Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., ... & Conte, P. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *New England Journal of Medicine*, 377(6), 523-533. DOI: 10.1056/NEJMoa1706450.

Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009). The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. *The oncologist*, 14(4), 320-368. <https://doi.org/10.1634/theoncologist.2008-0230>.

Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., ... & Pusztai, L. (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clinical cancer research*, 11(16), 5678-5685. <https://doi.org/10.1158/1078-0432.CCR-04-2421>.

Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., ... & Loi, S. (2015). The evaluation of tumor-infiltrating lymphocytes (TILs) in

breast cancer: recommendations by an International TILs Working Group
2014. *Annals of oncology*, 26(2), 259-271.
<https://doi.org/10.1093/annonc/mdu450>.

Schwartz, T. L., Mogal, H., Papageorgiou, C., Veerapong, J., & Hsueh, E. C.
(2013). Metaplastic breast cancer: histologic characteristics, prognostic factors
and systemic treatment strategies. *Experimental hematology & oncology*, 2, 1-
6. <https://doi.org/10.1186/2162-3619-2-31>.

Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E.,
... & Cardoso, F. (2015). Primary breast cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. *Annals of oncology*, 26, v8-
v30. <https://doi.org/10.1093/annonc/mdv298>.

Shah, A., Bloomquist, E., Tang, S., Fu, W., Bi, Y., Liu, Q., ... & Pazdur, R. (2018).
FDA approval: ribociclib for the treatment of postmenopausal women with
hormone receptor-positive, HER2-negative advanced or metastatic breast
cancer. *Clinical Cancer Research*, 24(13), 2999-3004.
<https://doi.org/10.1158/1078-0432.CCR-17-2369>.

Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014). Cancer statistics, 2014. *CA: a cancer
journal for clinicians*, 64(1), 9-29. <https://doi.org/10.3322/caac.21208>.

Siegel, R. L., Miller, K. D., & Jemal, A. (2015). Cancer statistics, 2015. *CA: a
cancer journal for clinicians*, 65(1), 5-29. <https://doi.org/10.3322/caac.21254>

Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. *CA: a
cancer journal for clinicians*, 69(1), 7-34. <https://doi.org/10.3322/caac.21551>

- Sinn, H. P., & Kreipe, H. (2013). A brief overview of the WHO classification of breast tumors, focusing on issues and updates from the 3rd edition. *Breast care*, 8(2), 149-154. <https://doi.org/10.1159/000350774>.
- Skriver, S. K., Jensen, M. B., Knoop, A. S., Ejlersen, B., & Laenkholm, A. V. (2020). Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. *Breast Cancer Research*, 22(1), 1-8. <https://doi.org/10.1186/s13058-020-01285-8>.
- Smyth, L. M., Tamura, K., Oliveira, M., Ciruelos, E. M., Mayer, I. A., Sablin, M. P., ... & Hyman, D. M. (2020). Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 E17K-mutant, ER-positive metastatic breast cancer. *Clinical Cancer Research*, 26(15), 3947-3957. <https://doi.org/10.1158/1078-0432.CCR-19-3953>.
- Starzer, A. M., Berghoff, A. S., & Bartsch, R. (2023). Biomarkers and translational research approaches in breast cancer—an update. *memo-Magazine of European Medical Oncology*, 16(1), 42-46. <https://doi.org/10.1007/s12254-022-00855-0>.
- Sun, Y. S., Zhao, Z., Yang, Z. N., Xu, F., Lu, H. J., Zhu, Z. Y., Shi, W., Jiang, J., Yao, P. P., & Zhu, H. P. (2017). Risk Factors and Preventions of Breast Cancer. *International journal of biological sciences*, 13(11), 1387–1397. <https://doi.org/10.7150/ijbs.21635>.

Sun, L., Wu, A., Bean, G. R., Hagemann, I. S., & Lin, C.-Y. (2021). Molecular Testing in Breast Cancer. *The Journal of Molecular Diagnostics*. doi:10.1016/j.jmoldx.2021.07.026

Sun, L., Zhu, Y., Qian, Q., & Tang, L. (2018). Body mass index and prognosis of breast cancer: An analysis by menstruation status when breast cancer diagnosis. *Medicine*, 97(26). doi: 10.1097/MD.00000000000011220.

Sun, C., Mezzadra, R., & Schumacher, T. N. (2018). Regulation and function of the PD-L1 checkpoint. *Immunity*, 48(3), 434-452. <https://doi.org/10.1016/j.immuni.2018.03.014>.

Tarantino, P., Morganti, S., & Curigliano, G. (2020). Biologic therapy for advanced breast cancer: recent advances and future directions. *Expert Opinion on Biological Therapy*, 20(9), 1009-1024. <https://doi.org/10.1080/14712598.2020.1752176>.

Telli, M. L., & Ford, J. M. (2010). PARP inhibitors in breast cancer. *Clin Adv Hematol Oncol*, 8(9), 629-635.

Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. H., McClure, L. A., Lichtensztajn, D., Ford, J. M., & Gomez, S. L. (2011). Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. *Breast cancer research and treatment*, 127(2), 471-478. <https://doi.org/10.1007/s10549-010-1173-8>.

- Tischkowitz, M., & Xia, B. (2010). PALB2/FANCN: recombining cancer and Fanconi anemia. *Cancer research*, 70(19), 7353-7359. <https://doi.org/10.1158/0008-5472.CAN-10-1012>.
- Thierry, A. R., El Messaoudi, S., Gahan, P. B., Anker, P., & Stroun, M. (2016). Origins, structures, and functions of circulating DNA in oncology. *Cancer and metastasis reviews*, 35, 347-376. <https://doi.org/10.1007/s10555-016-9629-x>
- Thomas, M., Kelly, E. D., Abraham, J., & Kruse, M. (2019, April). Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease. *In Seminars in oncology* (Vol. 46, No. 2, pp. 121-132). WB Saunders. <https://doi.org/10.1053/j.seminoncol.2019.03.002>.
- Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015). PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. *Nature Reviews Cancer*, 15(1), 7-24. <https://doi.org/10.1038/nrc3860>.
- Traoré, B., Koulibaly, M., Diallo, A., & Bah, M. (2019). Molecular profile of breast cancers in Guinean oncological settings. *The Pan African medical journal*, 33, 22. <https://doi.org/10.11604/pamj.2019.33.22.18189>
- Tremont, A., Lu, J., & Cole, J. T. (2017). Endocrine therapy for early breast cancer: updated review. *Ochsner Journal*, 17(4), 405-411.
- Tung, N. M., & Garber, J. E. (2018). BRCA 1/2 testing: therapeutic implications for breast cancer management. *British journal of cancer*, 119(2), 141-152. <https://doi.org/10.1038/s41416-018-0127-5>.

- Ulaner, G. A., Riedl, C. C., Dickler, M. N., Jhaveri, K., Pandit-Taskar, N., & Weber, W. (2016). Molecular Imaging of Biomarkers in Breast Cancer. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine*, 57 Suppl 1(Suppl 1), 53S–9S. <https://doi.org/10.2967/jnumed.115.157909>.
- Vocka, M., Zimovjanova, M., Bielcikova, Z., Tesarova, P., Petruzelka, L., Mateju, M., ... & Kleibl, Z. (2019). Estrogen receptor status oppositely modifies breast cancer prognosis in BRCA1/BRCA2 mutation carriers versus non-carriers. *Cancers*, 11(6), 738. <https://doi.org/10.3390/cancers11060738>.
- Vranic, S., Feldman, R., & Gatalica, Z. (2017). Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers. *Bosnian journal of basic medical sciences*, 17(1), 9–11. <https://doi.org/10.17305/bjbms.2016.1811>.
- Vuong, D., Simpson, P. T., Green, B., Cummings, M. C., & Lakhani, S. R. (2014). Molecular classification of breast cancer. *Virchows Archiv*, 465, 1-14. <https://doi.org/10.1007/s00428-014-1593-7>.
- Waks, A. G., & Winer, E. P. (2019). Breast cancer treatment: a review. *Jama*, 321(3), 288-300. doi:10.1001/jama.2018.19323.
- Wang, J., & Xu, B. (2019). Targeted therapeutic options and future perspectives for HER2-positive breast cancer. *Signal transduction and targeted therapy*, 4(1), 34. <https://doi.org/10.1038/s41392-019-0069-2>.
- Wimberly, H., Brown, J. R., Schalper, K., Haack, H., Silver, M. R., Nixon, C., ... & Rimm, D. L. (2015). PD-L1 expression correlates with tumor-infiltrating

- lymphocytes and response to neoadjuvant chemotherapy in breast cancer. *Cancer immunology research*, 3(4), 326-332. <https://doi.org/10.1158/2326-6066.CIR-14-0133>.
- Yadav, S., & Couch, F. J. (2019). Germline genetic testing for breast cancer risk: the past, present, and future. *American Society of Clinical Oncology Educational Book*, 39, 61-74. DOI: 10.1200/EDBK_238987.
- Yang, T. J., & Ho, A. Y. (2013). Radiation therapy in the management of breast cancer. *Surgical Clinics*, 93(2), 455-471. <https://doi.org/10.1016/j.suc.2013.01.002>.
- Yap, Y. S., Lu, Y. S., Tamura, K., Lee, J. E., Ko, E. Y., Park, Y. H., ... & Lee, S. C. (2019). Insights into breast cancer in the east vs the west: a review. *JAMA oncology*, 5(10), 1489-1496. doi:10.1001/jamaoncol.2019.0620.
- Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M., & Gelmon, K. A. (2010). Ki67 in breast cancer: prognostic and predictive potential. *The lancet oncology*, 11(2), 174-183. [https://doi.org/10.1016/S1470-2045\(09\)70262-1](https://doi.org/10.1016/S1470-2045(09)70262-1).
- Zangouri, V., Akrami, M., Tahmasebi, S., Talei, A., & Hesarooeih, A. G. (2018). Medullary breast carcinoma and invasive ductal carcinoma: a review study. *Iranian Journal of Medical Sciences*, 43(4), 365. <https://doi.org/10.21859/mci-sup-100>.
- Zardavas, D., Te Marvelde, L., Milne, R. L., Fumagalli, D., Fountzilias, G., Kotoula, V., ... & Loi, S. (2018). Tumor PIK3CA genotype and prognosis in early-stage

breast cancer: a pooled analysis of individual patient data. *Journal of Clinical Oncology*, 36(10), 981-990. doi: 10.1200/JCO.2017.74.8301.

Zhang, W. W., Wu, S. G., Ling, Y. H., Sun, J. Y., Long, Z. Q., Hua, X., ... & Lin, H. X. (2018). Clinicopathologic characteristics and clinical outcomes of pure type and mixed type of tubular carcinoma of the breast: a single-institution cohort study. *Cancer Management and Research*, 4509-4515. <https://doi.org/10.2147/CMAR.S177046>.

Zhao, P., Li, L., Jiang, X., & Li, Q. (2019). Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. *Journal of hematology & oncology*, 12(1), 1-14. <https://doi.org/10.1186/s13045-019-0738-1>.

Zhou, G. Q., Lv, J. W., Tang, L. L., Mao, Y. P., Guo, R., Ma, J., & Sun, Y. (2020). Evaluation of the national comprehensive cancer network and European society for medical oncology nasopharyngeal carcinoma surveillance guidelines. *Frontiers in oncology*, 10, 119. <https://doi.org/10.3389/fonc.2020.00119>.